ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian CancerBusiness Wire • 11/30/21
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial OfficerBusiness Wire • 11/16/21
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASHBusiness Wire • 11/04/21
ImmunoGen, Inc.'s (IMGN) CEO Mark Enyedy on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/29/21
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating ResultsBusiness Wire • 10/14/21
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21